Historique de carrière de Matthew D. Dallas
Anciens postes connus de Matthew D. Dallas
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ZEALAND PHARMA A/S | Directeur Financier/CFO | 07/10/2019 | 31/08/2022 |
| Investor Relations Contact | 07/10/2019 | 31/08/2022 | |
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Directeur/Membre du Conseil | 06/11/2018 | 03/02/2020 |
| Independent Dir/Board Member | 06/11/2018 | 03/02/2020 | |
| AVEO PHARMACEUTICALS, INC. | Directeur Financier/CFO | 01/06/2017 | 26/09/2019 |
| COLUCID PHARMACEUTICALS INC | Directeur Financier/CFO | 09/02/2015 | 01/03/2017 |
| Treasurer | 09/02/2015 | 01/03/2017 | |
| AVEO PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/07/2014 | 06/02/2015 |
| Treasurer | 01/07/2014 | 06/02/2015 |
Formation de Matthew D. Dallas
| University of Tennessee | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Danemark | 2 |
Opérationnelle
| Director of Finance/CFO | 3 |
| Treasurer | 2 |
| Comptroller/Controller/Auditor | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Entreprise privées | 2 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Matthew D. Dallas
- Expérience
